BRIEF published on 06/18/2025 at 07:05, 9 months 8 days ago PHAXIAM Therapeutics suspends trading of its shares Euronext Paris Innovative Treatments PHAXIAM Suspension Of Quotation Delisting Securities
PRESS RELEASE published on 06/18/2025 at 07:00, 9 months 8 days ago Inside Information / Other news releases PHAXIAM Therapeutics suspends trading shares for delisting on Euronext Paris market. No reimbursement to shareholders. Company focuses on innovative phage-based treatments for resistant bacterial infections Trading Delisting Suspension PHAXIAM Therapeutics Phage-based Treatments
BRIEF published on 06/05/2025 at 07:05, 9 months 21 days ago PHAXIAM Therapeutics Facing Potential Liquidation Amid Court Hearing Postponement Biopharmaceuticals Judicial Liquidation Court Hearing PHAXIAM Therapeutics Euronext Delisting
PRESS RELEASE published on 06/05/2025 at 07:00, 9 months 21 days ago Inside Information / Other news releases PHAXIAM Therapeutics announces new postponement of Offer Review Hearing by Lyon Commercial Court to June 11, 2025. Company to request delisting from Euronext Euronext Delisting Postponement PHAXIAM Therapeutics Lyon Commercial Court
BRIEF published on 03/14/2025 at 17:50, 1 year ago PHAXIAM Therapeutics seeks buyer in receivership Euronext Paris PHAXIAM Therapeutics Judicial Recovery Looking For A Buyer Extension Of Procedure
PRESS RELEASE published on 03/14/2025 at 17:45, 1 year ago Inside Information / Other news releases PHAXIAM Therapeutics launches bidding process to find buyers amid receivership, trading of shares to resume on Euronext Paris. Court decides on procedure extension on April 30, 2025 Euronext Paris Receivership PHAXIAM Therapeutics Court Decision Bidding Process
BRIEF published on 03/06/2025 at 18:01, 1 year ago PHAXIAM Therapeutics Enters Receivership and Delays Financial Results Trading Suspension Financial Results Delay PHAXIAM Receivership Biotech Challenges Court-appointed Administrator
PRESS RELEASE published on 03/06/2025 at 17:56, 1 year ago Inside Information / Other news releases PHAXIAM Therapeutics announces the opening of a receivership procedure and postponement of its 2024 financial results publication. The company continues operations under observation period Financial Results Biopharmaceutical Company PHAXIAM Therapeutics Receivership Procedure Phage-based Treatments
BRIEF published on 03/06/2025 at 11:45, 1 year ago Suspension of the Listing of PHAXIAM Therapeutics Euronext Paris Biopharmaceutical PHAXIAM Therapeutics Suspension Of Quotation Resistant Infections
BRIEF published on 12/30/2024 at 17:50, 1 year 2 months ago PHAXIAM Therapeutics: Promising results from the PhagoDAIR pilot study Infection Control PHAXIAM Therapeutics Phase II GLORIA PhagoDAIR Study Anti-S. Aureus Phages
Published on 03/26/2026 at 11:07, 44 minutes ago U.S. Mined and Refined Metals as well as Rare Earth Elements to Be Tokenized in Historic American Strategic Minerals and Datavault AI Deal
Published on 03/26/2026 at 11:00, 51 minutes ago Stagwell Expands the Harris Poll's Harrisquest Across Europe
Published on 03/26/2026 at 08:05, 3 hours 46 minutes ago Vanta Announces U.S. Ticker Symbol Change to VNTXF
Published on 03/26/2026 at 04:55, 6 hours 56 minutes ago Vanta Announces Capital Markets Initiatives to Strengthen Financial Position and Support Growth Initiatives
Published on 03/26/2026 at 11:03, 48 minutes ago EQS-Adhoc: VIDINEXT AG: Marketing agreement with Telekom Deutschland GmbH
Published on 03/26/2026 at 11:00, 51 minutes ago Genel Energy PLC: Posting of Annual Report and Notice of AGM
Published on 03/26/2026 at 11:00, 51 minutes ago Genel Energy PLC: Report on payments to governments for the year 2025
Published on 03/26/2026 at 11:00, 51 minutes ago ABB Ltd: ABB share buybacks - March 19, 2026 - March 25, 2026
Published on 03/26/2026 at 11:00, 51 minutes ago Independent study reveals 44% ROI with EQS Compliance Cockpit and payback in under six months
Published on 03/26/2026 at 07:30, 4 hours 21 minutes ago BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY
Published on 03/25/2026 at 18:31, 17 hours 20 minutes ago Strong investment performance and active roll-out of our strategy
Published on 03/25/2026 at 17:45, 18 hours 6 minutes ago Combined General Meeting on May 05, 2026: publication of the notice of Meeting
